SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

Rhea-AI Summary

SOPHiA GENETICS partners with Karkinos Healthcare to advance cancer research and personalized cancer care in India. The partnership aims to expand access to precision oncology and equip local health institutions with the tools and technology needed to practice data-driven medicine. Karkinos Healthcare will use the SOPHiA DDM™ Platform to advance research and streamline workflow for a variety of blood cancers and solid tumors, with a focus on precision medicine for the underprivileged population of India.

Medical Research Analyst

The partnership between SOPHiA GENETICS and Karkinos Healthcare represents a significant advancement in the field of precision oncology, particularly within the context of emerging markets such as India. By integrating the SOPHiA DDM™ Platform into Karkinos Healthcare's distributed cancer care network, there is an expectation of a substantial increase in the accuracy and speed of cancer diagnosis, especially for blood cancers and solid tumors. This integration will likely lead to the generation of large datasets that are critical for improving machine learning algorithms in genomic variant detection.

From a research standpoint, the collaboration is poised to provide invaluable insights into the genomic landscape of the Indian population, which has been underrepresented in global cancer genomics research. This could lead to the discovery of novel biomarkers and therapeutic targets that are specific to this demographic, potentially improving patient outcomes and creating opportunities for tailored therapies.

Healthcare Economist

The strategic partnership between SOPHiA GENETICS and Karkinos Healthcare has the potential to disrupt the traditional cancer care delivery model in India. By focusing on a 'Community as a Cancer Centre' approach, the initiative aims to democratize access to advanced cancer diagnostics and care, which can lead to a reduction in the economic burden of cancer on patients and the healthcare system. The digital 'hub and spoke' model allows for scalability and cost-effectiveness, potentially reducing the overall cost of cancer care.

Moreover, the emphasis on serving underprivileged populations aligns with broader public health objectives of increasing healthcare equity. This is particularly relevant in a country like India, where there is a significant disparity in healthcare access between urban and rural areas. The long-term economic impact could include reduced healthcare expenditures due to earlier detection and more effective treatment, as well as potential growth in the healthcare sector driven by increased demand for precision oncology services.

Market Research Analyst

The collaboration between SOPHiA GENETICS and Karkinos Healthcare could have a ripple effect on the precision medicine market, especially within low and middle-income countries. As SOPHiA GENETICS expands its global footprint, it sets a precedent for how cloud-native software and data-driven platforms can be leveraged in diverse healthcare settings. This could encourage other market players to explore similar partnerships, leading to increased competition and innovation.

Investors and stakeholders in the genomic and precision medicine sectors should monitor the outcomes of this partnership closely, as successful implementation could signal the viability of such technology in similar markets. This could influence investment trends and strategic decisions within the industry, potentially leading to increased funding for research and development in underserved regions.

SOPHiA GENETICS technology helps advance cancer research across India

SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care in India

BOSTON and ROLLE, Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries.

Karkinos Healthcare is a purpose-driven, technology-led oncology platform, focused on early detection, advanced diagnostics, and treatment delivery of common cancers, using its Distributed Cancer Care Network across India. Karkinos Healthcare provides end-to-end solutions for oncology ecosystem, including disease screening, diagnosis, surgery, chemotherapy, radiotherapy and comprehensive patient navigation through the care continuum, in addition to operating advanced research and development laboratories. The company is on a mission to create 'Community as a Cancer Centre' with an endeavour to serve one million patients annually by addressing the accessibility and affordability gaps in cancer care through a digitally curated hub and spoke and further spoke model, and not restrict cancer care to comprehensive centres alone.

"It is our continued goal to improve health outcomes for patients globally by expanding access to precision oncology and equipping local health institutions with the tools and technology needed to practice data-driven medicine," said Dr. Jurgi Camblong, CEO and Co-founder, SOPHiA GENETICS. "By aligning with Karkinos, who share the mutual goal, we can help increase the use of best-in-class cancer testing for rural and underserved communities around the world."

On this strategic partnership, Dr. R Venkataramanan, Founder and CEO, Karkinos Healthcare said, "Through collaborative research initiatives, Karkinos Healthcare aims to address the comprehensive genomic landscape identification for Indian population, with a focus on precision medicine. This alliance will have the potential to generate evidence and world-class research for faster and accurate diagnosis and better control and management of cancers, particularly for the underprivileged population of our country."

The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect rare and challenging cases. Karkinos Healthcare will use SOPHiA GENETICS' technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma. In addition, the company will analyse solid tumours for a variety of cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers.

The SOPHiA DDM™ Platform offers tailored NGS-based workflows to streamline processes – from sample to report – to accelerate analysis. By using the SOPHiA DDM™ Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine.

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers. 

Product Disclaimer
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS: Forward-Looking Statement
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

About Karkinos Healthcare
Karkinos Healthcare is a purpose driven technology-led oncology health care platform for early detection and diagnosis of common cancers. The organisation espouses use of a distributed cancer care network, while working with a network of healthcare institutions and domain experts within the ecosystem, with an aim to provide comprehensive cancer care closer to individuals' homes.

Tata Group, Reliance Industries, Mayo Clinic, and Rakuten Medical Inc. are among the World's leading organizations that have invested in Karkinos Healthcare. The company has also partnered with Tata Memorial Hospital, Guys and St Thomas NHS Foundation Trust (UK), and has inked several research collaborations with leading academic institutions in the United States to stay on the cutting edge of oncology treatment and care. To learn more, visit https://www.karkinos.in/about-us/

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-and-karkinos-healthcare-forge-strategic-partnership-to-advance-cancer-research-in-india-302034183.html

SOURCE SOPHiA GENETICS

FAQ

What is the partnership between SOPHiA GENETICS and Karkinos Healthcare about?

The partnership aims to advance cancer research and personalized cancer care in India, focusing on expanding access to precision oncology and equipping local health institutions with the tools and technology needed to practice data-driven medicine.

How will Karkinos Healthcare use the SOPHiA DDM™ Platform?

Karkinos Healthcare will use the SOPHiA DDM™ Platform to advance research and streamline workflow for a variety of blood cancers and solid tumors, with a focus on precision medicine for the underprivileged population of India.

What types of cancer will be analyzed by Karkinos Healthcare using SOPHiA GENETICS' technology?

Karkinos Healthcare will analyze a variety of blood cancers, including Myeloid cancer and Lymphoma, as well as solid tumors for cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers.

Who are the key figures involved in the partnership?

Dr. Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, and Dr. R Venkataramanan, Founder and CEO of Karkinos Healthcare, are the key figures involved in the partnership.

What is the mission of Karkinos Healthcare?

Karkinos Healthcare aims to serve one million patients annually by addressing the accessibility and affordability gaps in cancer care through a digitally curated hub and spoke model, and not restrict cancer care to comprehensive centres alone.